Effect of Cinnamon as a supplementary Medicine in Major Depressive Disorders

Evaluation of antidepressant effect of Cinnamomum zeylanicum as an adjunct with conventional antidepressant therapy - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/04/085695

Enrollment

140

Registered

2025-04-25

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G- Mental Health

Interventions

Intervention1: Administration of conventional antidepressant drugs and herbal drug by oral route: A total number of 70 patients will be included in treatment group and will be given conventional treat

Eligibility

Inclusion criteria

Inclusion criteria: -Newly diagnosed MDD patients with moderate to severe depression as per Beck’s Depressive inventory (BDI)16 and ICD- 11 WHO guidelines. -Patients willing to give Informed Consent

Exclusion criteria

Exclusion criteria: -Patients with BDI score lesser than 21. -Pregnant and lactating females. -Patients with bipolar disorder. -Patients with other psychiatric disorders. -Patients with other debilitating disorders. -Patient with other intellectual disorders. -Patients of substance abuse disorders.

Design outcomes

Primary

Measure	Time frame
BDI Score at the end of 8 weeks of TreatmentTimepoint: 8 weeks	—

Secondary

Measure	Time frame
nilTimepoint:	—

Countries

India

Contacts

Public ContactPinki Vishwakarma

LLRM Medical College, Meerut

shubhamyadav.619@live.com8090457728

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026